婦女癌症防治中心
主持人：朱堂元 Tang-Yuan Chu
聯絡電話：TEL03-8561825 轉15610
電子郵箱：hidrchu@gmail.com
現職：
電子郵箱：hidrchu@gmail.com
現職：
- 佛教慈濟醫療財團法人花蓮慈濟醫院 婦女癌症防治中心主任
- 慈濟學校財團法人慈濟大學 醫學科學研究所教授、學組召集人
- 亞太婦科感染及腫瘤學會(AOGIN)創始人、常務理事、台灣代表
- 衛生福利部子宮頸癌預防諮詢專家、癌症防治中心計畫評審委員
- 台灣婦產科醫學會理事、學術委員、專科醫師人力規劃委員
- 台灣婦科腫瘤醫學會常務理事
- 中華民國婦癌醫學會常務理事
Professor Chu received his MD degree from National Defense Medical Center of Taiwan and PhD degree from Cornell University Medical Center. He was trained in Obstetrics and Gynecology and Gynecologic Oncology in Tri-Service General Hospital, Taiwan.
In 2005, he was appointed to Tzu Chi Medical Center, Hualien, Taiwan, acting as chiefs of Department of Obstetrics and Gynecology, Department of Research and director of the Center for Prevention and Therapy of Gynecological Centers.
He was the director of Graduate Institute of Medical Sciences of National Defense Medical Center, and the founder and director of Institute of Clinical Medicine and Institute of Medical Sciences in Tzu Chi University, Taiwan .
Professor Chu’s research focuses on the developmental mechanism of cervical cancer and the ovarian high-grade serous carcinoma (HGSC) and the clinical applications. Special effort was paid on the role of stromal sex-hormone receptors in the development of cervical cancer, and the initiation and promotion of HGSC originating in the fallopian tube epithelium. His research team has recently discovered multiple carcinogens and mechanisms relating to ovulation, responsible for the mutagenesis, mitogenesis and transformation of fallopian tube epithelium in the context of p53 loss. With the in-vitro and in-vivo study systems as well as clinical cohorts and tissue banking, his team is also developing drugs for chemoprevention and biomarkers for early detection of these two cancers.
In 2005, he was appointed to Tzu Chi Medical Center, Hualien, Taiwan, acting as chiefs of Department of Obstetrics and Gynecology, Department of Research and director of the Center for Prevention and Therapy of Gynecological Centers.
He was the director of Graduate Institute of Medical Sciences of National Defense Medical Center, and the founder and director of Institute of Clinical Medicine and Institute of Medical Sciences in Tzu Chi University, Taiwan .
Professor Chu’s research focuses on the developmental mechanism of cervical cancer and the ovarian high-grade serous carcinoma (HGSC) and the clinical applications. Special effort was paid on the role of stromal sex-hormone receptors in the development of cervical cancer, and the initiation and promotion of HGSC originating in the fallopian tube epithelium. His research team has recently discovered multiple carcinogens and mechanisms relating to ovulation, responsible for the mutagenesis, mitogenesis and transformation of fallopian tube epithelium in the context of p53 loss. With the in-vitro and in-vivo study systems as well as clinical cohorts and tissue banking, his team is also developing drugs for chemoprevention and biomarkers for early detection of these two cancers.
研究方向
- 癌症遺傳與表觀遺傳
- 癌症與幹細胞發育
- 人類乳突病毒與子宮頸癌、卵巢癌
專長
- 婦癌手術、達文西機械手臂手術、腹腔鏡微創手術
- 婦科腫瘤、婦科感染、骨盆腔疾病、月經疾病、更年期疾病
- 婚前孕前健康遺傳諮詢
- 婦癌篩檢、婦癌診斷、婦癌治療、婦癌病因學及預防醫學
- 婦癌臨床試驗
學歷
- 美國Sloan-Kettering癌症中心博士研究員
- 美國康乃爾大學醫學院細胞生物及遺傳學博士
- 國防醫學院醫學系學士
經歷
- 慈濟醫學中心婦產部主任
- 慈濟大學醫學科學研究所教授、創所所長
- 慈濟大學臨床醫學研究所教授、創所所長
- 慈濟醫學中心研究部主任
- 國防醫學院醫學科學研究所教授、所長
- 國防醫學院婦產學科副教授、教授
- 三軍總醫院住院醫師、總醫師、主治醫師、婦科主任
- 台灣安寧緩和療護專科醫師
- 台灣婦癌專科醫師(2003年起，創始會員)
- 台灣婦產科專科醫師(1986年起)
相關學會會員資格
- 中華民國婦癌醫學會
- 台灣婦產科醫學會
- 台灣婦科醫學會
- 台灣婦癌醫學會
個人獎項
| 2016年 | 慈濟醫院研究卓越獎 |
| 2014年 | 慈濟醫院優秀研究論文獎｢資深人員組｣第二名 |
| 2010年 | 國防醫學院傑出校友獎 |
| 2009年 | 第十四屆台灣癌症聯合學術年會優秀壁報論文獎（一項） |
| 2008年 | 慈濟醫院優秀臨床研究論文獎｢資深人員組｣第一名 |
| 2008年 | 第十三屆台灣癌症聯合學術年會優秀壁報論文獎（三項） |
| 2007年 | 第十二屆台灣癌症聯合學術年會優秀壁報論文獎（三項） |
國內外學術期刊與研究審查委員
- 國家衛生研究院婦癌臨床指引編撰專家
- 科技部｢婦幼醫學｣學門複審委員
重要會議邀請演講
- 2016 台灣癌症聯合學術年會
- 2016 第三屆湖南省婦科腫瘤國際論壇
- 2015 Biennial conference of Asia Oceania Research Organisation on Genital Infection and Neoplasia(AOGIN)
- 2014 The 6th Biennial conference of Asia Oceania Research Organisation on Genital Infection and Neoplasia(AOGIN)
研究計畫
| 補助/委託機構 | 計畫名稱 | 起迄日期 |
| 慈濟醫療志業任務導向 之跨院校合作研究計畫 |
以排卵濾泡液之致癌因子作為排卵致癌風險之生物標記研究 | 108.01.01-108.12.31 |
| 科技部 | 建構排卵誘發輸卵管癌化的之基因轉殖小鼠模式：高級別漿液性癌致癌機制與化學預防之實證研究 | 107.08.01-110.07.31 |
| 花蓮慈濟醫院 | 黃體素受體在輸卵管上皮癌化的角色及成為治療目標的可行性研究 | 106.01.01-108.12.31 |
| 科技部 | 高分化級別漿液性卵巢癌自輸卵管上皮癌化之研究：破解癌化過程之基因變化 | 105.08.01-107.07.31 |
| 花蓮慈濟醫院 | 氧化血紅素在排卵 ROS 誘發輸卵管上皮癌化所扮演的角色 | 105.01.01-105.12.31 |
| 慈濟醫療志業 跨院校合作研究計畫 |
探討黃體素及選擇性黃體素受體調節劑（SPRM）對不同癌化程度的輸卵管分泌細胞之治療效果 | 104.08.01-107.07.31 |
| 生技醫藥國家型 臨床試驗計畫 |
Tamoxifen與Letrozole在復發或持續性子宮頸鱗狀上皮癌之療效及新生物標記：多中心、隨機分配二期臨床試驗 | 103.12.01-105.05.31 |
| 科技部 | 子宮頸基質雌激素受體在子宮頸癌化扮演的角色 | 103.08.01-105.07.31 |
| 花蓮慈濟醫院 | 以低毒性 Tamoxifen 作為復發或治療無效子宮頸癌搶救治療之臨床試驗 | 103.01.01-104.12.31 |
| 國科會性別科技 | 雌激素與子宮頸癌等女性賀爾蒙依賴性癌症發生的關係：健康資料串聯研究與臨床前期研究 | 102.08.01-103.07.31 |
| 慈濟醫院跨院區計畫 | 排卵與環境因子對輸卵管繖部癌化之研究 | 102.01.01-104.12.31 |
著作目錄
1. Hsu CF, Huang HS, Chen PC, Ding DC, Chu TY*. IGF-axis confers transformation and regeneration of fallopian tube fimbria epithelium upon ovulation. EBioMedicine. 2019 Mar;41:597-609.
2. Huang HS, Chen PC, Chu SC, Lee MH, Huang CY, Chu TY*. Ovulation sources coagulation protease cascade and hepatocyte growth factor to support physiological growth and malignant transformation. Neoplasia. 2021 Nov;23(11):1123-1136.
3. Hsu CF, Chen PC, Seenan V, Ding DC, Chu TY*. Ovulatory follicular fluid facilitates the full transformation process for the development of high-grade serous carcinoma. Cancers (Basel). 2021 Jan 26;13(3):468
4. Wu NY, Fang C, Huang HS, Wang J, Chu TY*. Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions. Mod Pathol. 2020 Jan, 33(1):29-37.
5. Wu N, Zhang X, Wang Z, Zhang X, Fang C, Li H, Zhu M, Wang Y, Liao Q, Chu TY*, Wang J*. Progesterone prevents HGSOC by promoting precancerous cell pyroptosis via inducing fibroblast paracrine. iScience. 2023 Mar 29;26(4):106523
2. Huang HS, Chen PC, Chu SC, Lee MH, Huang CY, Chu TY*. Ovulation sources coagulation protease cascade and hepatocyte growth factor to support physiological growth and malignant transformation. Neoplasia. 2021 Nov;23(11):1123-1136.
3. Hsu CF, Chen PC, Seenan V, Ding DC, Chu TY*. Ovulatory follicular fluid facilitates the full transformation process for the development of high-grade serous carcinoma. Cancers (Basel). 2021 Jan 26;13(3):468
4. Wu NY, Fang C, Huang HS, Wang J, Chu TY*. Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions. Mod Pathol. 2020 Jan, 33(1):29-37.
5. Wu N, Zhang X, Wang Z, Zhang X, Fang C, Li H, Zhu M, Wang Y, Liao Q, Chu TY*, Wang J*. Progesterone prevents HGSOC by promoting precancerous cell pyroptosis via inducing fibroblast paracrine. iScience. 2023 Mar 29;26(4):106523